IXICO plc Appointment of Giulio Cerroni as CEO (2905U)

TIDMIXI

RNS Number : 2905U

IXICO plc

17 January 2017

17 January 2017

IXICO plc

("IXICO" or the "Company")

IXICO appoints Giulio Cerroni as Chief Executive Officer

Brings extensive experience in both scaling operations to build businesses and supplying sophisticated products and services to the pharmaceutical and research communities

IXICO, the brain health company, today announces that Giulio Cerroni will be appointed to the Board as Chief Executive Officer (CEO) with effect from 6 February 2017. Derek Hill, the co-founder and current CEO, will remain on the board and continue to serve the Company as an executive director. Derek will have specific responsibility for deepening the Company's relationships with major pharmaceutical companies, key opinion leaders and government agencies as well as advancing IXICO's pioneering range of digital technologies.

Giulio, aged 55, has almost 30 years of international management experience gained in life sciences and diagnostics sectors. He was previously Managing Director of the Genomics division of LGC Group (LGC), the international life sciences measurement and testing company. At LGC, he grew divisional revenues threefold and doubled profits through a combined organic and acquisitive growth strategy into an organisation with 480 staff based in ten locations globally. Between April 2015 and August 2016, he led and integrated three US based acquisitions, significantly enhancing LGC's position as a leading global genomics tools platform. Previously, Giulio held a variety of senior roles at Thermo Fisher Scientific, Abgene, Anachem, ICN Biomedicals and Du Pont. He has a BSc from Cardiff University and an MBA from Warwick Business School.

Charles Spicer, Non-Executive Chairman of IXICO, commented: "We are delighted to welcome Giulio to IXICO where he will work with the executive team to lead the business into its next phase of growth. Giulio brings extensive experience in both scaling operations to build businesses and supplying sophisticated products and services to the pharmaceutical and research communities. On behalf of the Board, I would like to acknowledge Derek's many contributions and his vision that has enabled IXICO to establish itself as a leading company focused on applying innovative digital technologies to brain health. We look forward to continuing to build the business together."

Giulio Cerroni added: "I am very excited to be joining IXICO to lead the Company's next stage of growth towards becoming the global leader in digital healthcare technologies for the brain health market. Brain diseases are an area of huge unmet need and provide a significant growth opportunity for IXICO's digital health technology platform. In particular, I believe that our scientific leadership in medical data analysis makes IXICO uniquely placed to become the global partner of choice to the pharmaceutical industry as they integrate digital healthcare technologies as part of their overall product offering."

Additional information:

   (i)         Giulio Cerroni does not have any current directorship or partnerships 

(ii) in the last five years, Giulio Cerroni has been but is no longer a director or partner of the following companies or partnerships:

Biosearch Technologies A/S

Biosearch Technologies Inc

Douglas Scientific LLC

(iii) Giulio Cerroni has confirmed that there is no other additional information to be disclosed under Schedule 2 (g) of the AIM Rules.

For further information please contact:

 
 IXICO plc 
  Charles Spicer, Non-Executive Chairman     Tel: +44 20 
                                             3763 7499 
 Shore Capital (Nomad and Broker)          Tel: +44 20 
  Bidhi Bhoma / Edward Mansfield            7408 4090 
 
 FTI Consulting Limited (Investor          Tel: +44 20 
  Relations)                                3727 1000 
  Simon Conway/Mo Noonan/Matthew Moss 
 

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAQQLFFDFFEBBK

(END) Dow Jones Newswires

January 17, 2017 02:00 ET (07:00 GMT)